EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Entry into a Material Definitive AgreementItem 1.01Entry into a Material Definitive Agreement.
On November 7, 2017, Evoke Pharma, Inc. (the Company) entered into a Manufacturing Services Agreement (the Manufacturing Agreement) with Patheon UK Limited, a wholly-owned subsidiary of Thermo Fisher, Inc. (Patheon), to which Patheon has agreed to manufacture commercial quantities of Gimoti, the Companys nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Under the terms of the Manufacturing Agreement, the Company is required to purchase a certain percentage of its requirements for its Gimoti product intended for comm…
Read the full article at: https://marketexclusive.com/evoke-pharma-inc-nasdaqevok-files-an-8-k-entry-into-a-material-definitive-agreement-5/2017/11/